Objective To investigate and observe clinical effect of blood glucose control of subcutaneous injection of IDegAsp or IAsp30 in treatment of type 2 diabetes patients with poor blood glucose control,which is coverted from oral hypoglycemic drugs.Methods The paper chose 60 patients with type 2 diabetes with poor blood glucose control in Endocrinology Department of Fengxian County TCM Hospital from January 2021 to June 2022,treated with oral hypoglycemic drugs.According to different treatment methods,patients were divided into two groups:degludec aspart insulin group(IDegAsp group)and insulin aspart 30 group(IAsp30 group),with 30 cases in each group.Incidence of blood glucose,hypoglycemia,and blood glucose fluctuation was compared between two groups after two weeks of intensive treatment.Results After 2 weeks of intensive insulin therapy,blood glucose levels in the IdiogAsp group were lower than the IAsp30 group,difference was statistically significant(P<0.05).Incidence of hypoglycemia in the IdegAsp group was 6.7%,lower than 26.7%in the IAsp30 group,difference was statistically significant(P<0.05).The fluctuation range of blood glucose in the IdiogAsp group was(2.13±0.82)mmol/L,lower than(4.65±1.11)mmol/L in the IAsp30 group,difference was statistically significant(P<0.05).Conclusion During the intensive insulin treatment of type 2 diabetes patients,IDegAsp twice daily injection scheme is better than IAsp30 twice daily injection scheme,which has advantages of better glucose control,lower blood glucose fluctuation,and lower risks of hypoglycemia.
维普
万方数据